Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...
Pharmabiz15h
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...
Telix Pharmaceuticals Limited: Illuccix Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
GlobalData on MSN1d
Telix’s prostate cancer imaging agent approved in Brazil
Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Stockhead on MSN1d
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
Le Lézard1d
Great-West Lifeco releases updated Supplemental Information Package for 2025
Great-West Lifeco (GWO) has released an update for its Supplemental Information Package (SIP) for 2025 for analysts and ...
Le Lézard1d
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHTtm
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...